A PDE5 inhibitor
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Mirodenafil (hydrochloride)

Item No. 29045

Technical Information
Formal Name
5-ethyl-3,5-dihydro-2-[5-[[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl]-2-propoxyphenyl]-7-propyl-4H-pyrrolo[3,2-d]pyrimidin-4-one, dihydrochloride
CAS Number
862189-96-6
Synonyms
  • SK3530
Molecular Formula
C26H37N5O5S • 2HCl
Formula Weight
Purity
≥95%
Formulation
A crystalline solid
DMF: 25 mg/mlDMSO: 25 mg/mlDMSO:PBS (pH 7.2) (1:9): 0.1 mg/mlEthanol: 10 mg/ml
λmax
211, 250 nm
SMILES
O=C1C2=C(C(CCC)=CN2CC)NC(C3=CC(S(N4CCN(CCO)CC4)(=O)=O)=CC=C3OCCC)=N1.Cl.Cl
InChi Code
InChI=1S/C26H37N5O5S.2ClH/c1-4-7-19-18-30(6-3)24-23(19)27-25(28-26(24)33)21-17-20(8-9-22(21)36-16-5-2)37(34,35)31-12-10-29(11-13-31)14-15-32;;/h8-9,17-18,32H,4-7,10-16H2,1-3H3,(H,27,28,33);2*1H
InChi Key
CKPHITUXXABKDL-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    Mirodenafil is a phosphodiesterase 5 (PDE5) inhibitor.1 It increases penile intracavernosal pressure (ICP) in a rat model of diabetes induced by streptozotocin (STZ; Item No. 13104) and in a rat model of cavernosal nerve injury when administered at doses of 1 and 10 mg/kg, respectively.1,2 Mirodenafil (4 mg/kg per day) decreases bladder wall submucosal fibrosis and degeneration in a rat model of chronic bladder ischemia.3 It also decreases bladder overactivity in a female rat model of partial bladder outlet obstruction.4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Park, K., Cho, S.Y., and Kim, S.W. Erectile response to type 5 phosphodiesterase inhibitor could be preserved with the addition of simvastatin to conventional insulin treatment in rat model of diabetes. Int. J. Androl. 34(5 Pt 2), e468-e474 (2011).

    2. Kim, H., Sohn, D.W., Kim, S.D., et alThe effect of mirodenafil on the penile erection and corpus cavernosum in the rat model of cavernosal nerve injury. Int. J. Impot. Res. 22(5), 291-297 (2010).

    3. Choi, H., Bae, J.H., Shim, J.S., et alMirodenafil prevents bladder dysfunction induced by chronic bladder ischemia in rats. Int. Neurourol. J. 19(1), 19-26 (2015).

    4. Kang, J.Y., Kim, E.K., and Kim, K.M. Effects of mirodenafil, a phosphodiesterase-5 inhibitor, on female rat bladder in a partial bladder outlet obstruction model: Physiological and immunohistochemical aspects. Korean J. Urol. 54(5), 339-344 (2013).